NCT00005796View on ClinicalTrials.gov

Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 29, 2000

Primary Completion Date

June 30, 2003

Study Completion Date

December 31, 2011

Conditions
Bone Marrow SuppressionBrain and Central Nervous System TumorsDrug/Agent Toxicity by Tissue/Organ
Interventions
PROCEDURE

filgrastim

GCSF is given after chemo administration

BIOLOGICAL

gene therapy

stem cells are collected and given back to the patients after chemotherapy adminstration

DRUG

lomustine

chemotherapy is administered every 21 days

DRUG

procarbazine hydrochloride

chemotherapy is administered every 21 days.

DRUG

vincristine sulfate

chemotherapy is administered every 21 days

PROCEDURE

in vitro-treated peripheral blood stem cell transplantation

stem cells are reinfused after chemotherapy administration

Trial Locations (2)

46202-5265

Indiana University Cancer Center, Indianapolis

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Indiana University Melvin and Bren Simon Cancer Center

OTHER

lead

Indiana University

OTHER

NCT00005796 - Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors | Biotech Hunter | Biotech Hunter